[The role of radiotherapy in the treatment of Hodgkin's disease].
Twenty-two patients with Hodgkin's disease were treated at Kanazawa University between 1975 and 1982. Patients in stage I or II were treated with radiotherapy. Those in stage III or IV underwent combination chemotherapy (MOPP) with or without radiotherapy. Twenty patients have achieved a complete remission (90.9%). The 10-year survival rate of all patients is 90%: 100% for patients in stage I or II and 73% for patients in stage III or IV. Thus, radiotherapy can be recommended as a primary treatment for patients in stage I or II while MOPP with radiotherapy could be effective for those in stage III or IV.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D011879:Radiotherapy Dosage; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone